Can-Fite BioPharma (CANF) News Today $0.69 -0.01 (-1.14%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.69 0.00 (-0.01%) As of 08/8/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Can-Fite BioPharma Ltd.: Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment MilestoneJuly 30, 2025 | finanznachrichten.dePancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment MilestoneJuly 30, 2025 | finance.yahoo.comPancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment MilestoneJuly 30, 2025 | globenewswire.comCan-Fite BioPharma Ltd.: Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular DementiaJuly 28, 2025 | finanznachrichten.deBreakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular DementiaJuly 28, 2025 | finance.yahoo.comCan-Fite BioPharma Ltd. Announces $5.0 Million Public Offering with Potential for Additional $10.0 Million in Gross ProceedsJuly 28, 2025 | quiverquant.comQCan-Fite Announces Up To $15.0 Million Public OfferingJuly 28, 2025 | globenewswire.comCan-Fite BioPharma’s Piclidenoson Shows Promise in Vascular Dementia TreatmentJuly 28, 2025 | tipranks.comBreakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular DementiaJuly 28, 2025 | globenewswire.comCANF Can-Fite BioPharma Ltd. - Seeking AlphaJune 27, 2025 | seekingalpha.comCan-Fite BioPharma Ltd. (CANF) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comCan-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in BostonJune 16, 2025 | finance.yahoo.comCan-Fite BioPharma says medical centers seek authorization for namodenosonApril 18, 2025 | markets.businessinsider.comFollowing FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their PatientsApril 17, 2025 | globenewswire.comCan-Fite Reports 2024 Financial Results and Clinical UpdateApril 14, 2025 | markets.businessinsider.comCan-Fite to Generate $685M in Projected Future Revenues from its PartnershipsApril 14, 2025 | finance.yahoo.comCan-Fite BioPharma Secures $3 Million in Direct OfferingApril 14, 2025 | tipranks.comCan-Fite Announces $3.0 Million Registered Direct Offering of American Depositary SharesApril 14, 2025 | globenewswire.comCan-Fite BioPharma Initiates Pivotal Phase 3 Study for Oral Drug Piclidenoson in Psoriasis TreatmentMarch 26, 2025 | nasdaq.comCan-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved ProtocolMarch 24, 2025 | markets.businessinsider.comCan-Fite BioPharma Projects $325 Million in Revenue from Piclidenoson Under Veterinary Partnership with VetbiolixMarch 22, 2025 | nasdaq.comCan-Fite BioPharma Initiates Phase II Clinical Study for Piclidenoson in Patients with Lowe SyndromeMarch 21, 2025 | nasdaq.comCan-Fite BioPharma to initiate Phase II study in Lowe SyndromeMarch 21, 2025 | markets.businessinsider.comCan-Fite BioPharma Advances Canine Osteoarthritis Treatment with Vetbiolix PartnershipMarch 20, 2025 | tipranks.comCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion MarketMarch 20, 2025 | globenewswire.comCan-Fite BioPharma Ltd.: Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with PiclidenosonMarch 19, 2025 | finanznachrichten.deCan-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with PiclidenosonMarch 19, 2025 | globenewswire.comCan-Fite announces FDA approved compassionate use treatment of NamodenosonMarch 18, 2025 | msn.comCan-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer PatientMarch 18, 2025 | tmcnet.comFDA Approves Compassionate Use of Can-Fite’s Namodenoson for Pancreatic CancerMarch 18, 2025 | tipranks.comCan-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological BenefitsMarch 3, 2025 | globenewswire.comDisappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonFebruary 18, 2025 | finance.yahoo.comDisappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonFebruary 18, 2025 | finance.yahoo.comCan-Fite reports disappearance of decompensated liver cirrhosis episodesFebruary 18, 2025 | markets.businessinsider.comCan-Fite’s Namodenoson Shows Promise in Treating Liver CirrhosisFebruary 18, 2025 | tipranks.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25February 10, 2025 | finance.yahoo.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25February 10, 2025 | globenewswire.comCan-Fite BioPharma to Present Namodenoson at Upcoming BIO CEO ConferenceFebruary 5, 2025 | tipranks.comCan-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025February 5, 2025 | globenewswire.comCan-Fite BioPharma secures US patent for NamodenosonJanuary 28, 2025 | msn.comCan-Fite BioPharma announces U.S. patent office granted patent to NamodenosonJanuary 28, 2025 | markets.businessinsider.comCan-Fite Wins Patent, Shares FlatJanuary 27, 2025 | baystreet.caUS Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity DrugJanuary 27, 2025 | markets.businessinsider.comCan-Fite BioPharma Secures US Patent for Anti-Obesity Drug NamodenosonJanuary 27, 2025 | tipranks.comD. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’January 1, 2025 | markets.businessinsider.comRecognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug NamodenosonDecember 30, 2024 | markets.businessinsider.comRecognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug NamodenosonDecember 30, 2024 | globenewswire.com8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugDecember 4, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVNovember 22, 2024 | finanznachrichten.deCan-Fite Biopharma Ltd. ADRNovember 20, 2024 | wsj.com Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address CANF Media Mentions By Week CANF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CANF News Sentiment▼0.000.50▲Average Medical News Sentiment CANF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CANF Articles This Week▼01▲CANF Articles Average Week Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Acurx Pharmaceuticals News Dogwood Therapeutics News X4 Pharmaceuticals News Aprea Therapeutics News Soligenix News Sonnet BioTherapeutics News Chromocell Therapeutics News Addex Therapeutics News Cellectar Biosciences News Synaptogenix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CANF) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
